Psoriasis treatment based on Weizmann Institute Research passes phase II clini...( Psoriasis is a chronic skin disease wit...)

Psoriasis is a chronic skin disease with as yet no cure that affects approximately 4.5 million people in the U.S. and 5.7 million people in Europe. About 10% of these people develop chronic inflammation of the joints called psoriatic arthritis. In clinical trials testing a drug based on the discovery of Prof. David Wallach of the Weizmann Institute's Biological Chemistry Department, the condition of psoriasis and psoriatic arthritis patients was greatly improved. The treatment had no adverse effects.

The results were reported by the Swiss-based company Serono that produces this drug in their Israel-based subsidiary Interpharm Laboratories. Interpharm was founded by Serono 25 years ago for the application of Weizmann Institute discoveries for therapy.

The drug, called Onercept, or r-hTBP-1, caused significant improvement in the patients' Psoriasis Area and Severity Index (PASI) score. PASI is the globally accepted measure of treatment efficacy in this indication. After 12 weeks of therapy, 54% of patients receiving Onercept demonstrated 75% or greater PASI score improvement. Only 12% of patients on placebo exhibited the same level of improvement. In addition, 74% of patients treated with Onercept achieved 50% or greater PASI score improvement, versus 26% in the placebo group.

Over the 12-week treatment period patients treated with onercept experienced a significant improvement in quality of life, based on the standard measurements of Short Form 36 (SF-36) and Dermatology Life Quality Index (DLQI).

As a result of this positive outcome, Serono plans to initiate Phase III trials in psoriasis with onercept later this year.

The drug works by neutralizing a hormone called "tumor necrosis factor" (TNF), which is produced by the immune system in response to injury or infection. In various inflammatory diseases, TNF production becomes excessive, leading to the destruction of healthy tissue. In search for natural inhibitors of TNF,
'"/>

Contact: Alex Smith
Alex_smith@margeotes.com
212-460-0563
American Committee for the Weizmann Institute of Science
11-Aug-2003

Page: 1 2
Related biology news :

1. Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
2. Leader in cancer treatment and prevention research honored
3. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
4. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
5. New treatment for fibromyalgia
6. The impact of genetic variations on the treatment of early rheumatoid arthritis
7. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
8. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
9. Colleagues to recognize research leadership in cancer detection, prevention and treatment
10. New view of leukemia cells identifies best treatment options, Stanford researchers say
11. Genetic model for devastating form of paraplegia suggests new treatments